Dermatology Clinical: Oral Presentation

FC02.7: Deucravacitinib in plaque psoriasis: 3-year safety and efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials

Presenter: April W. Armstrong, University of California Los Angeles, Los Angeles, CA, USA

Presentation date and time: 12 October, 11:15 AM-11:25 AM CET

Location: Messe Berlin Congress Center (Room M1+2)

Dermatology Clinical: Online e-Posters

P2448: Deucravacitinib in plaque psoriasis: maintenance of response over 3 years in the phase 3 POETYK PSO-1 and PSO-2 trials

Lead author: Bruce Strober, Yale University School of Medicine, New Haven, CT, USA

P2546: Deucravacitinib, a selective, allosteric TYK2 inhibitor, 
in plaque psoriasis: efficacy and maintenance of response over 
3 years with continuous treatment in Asian patients in the global phase 3 POETYK PSO-1 trial

Lead author: Shinichi Imafuku, Fukuoka University Hospital, Fukuoka, Japan

P2604: Deucravacitinib, an allosteric, selective tyrosine kinase 2 inhibitor, in plaque psoriasis: long-term safety results of patients from Asia in the phase 3 POETYK PSO-1 and PSO-3 trials

Lead author: Shinichi Imafuku, Fukuoka University Hospital, Fukuoka, Japan

P2443: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: efficacy by baseline demographics and disease characteristics in the phase 3 POETYK PSO-3 trial

Lead author: Jianzhong Zhang, Peking University People’s Hospital, Beijing, China

P2444: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: efficacy by prior treatment in the phase 3 POETYK PSO-3 trial

Lead author: Jianzhong Zhang, Peking University People’s Hospital, Beijing, China

P2550: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor: influence of comorbidities on safety and efficacy in Asian patients in the phase 3 POETYK PSO-3 trial

Lead author: Yangfeng Ding, Shanghai Skin Disease Hospital, Shanghai, China

P2542: Deucravacitinib, an oral, selective, tyrosine kinase 2 inhibitor: improvement in scalp psoriasis in patients from Asia in the phase 3 POETYK PSO-3 and PSO-4 trials

Lead author: Shinichi Imafuku, Fukuoka University Hospital, Fukuoka, Japan

P2430: Deucravacitinib long-term efficacy in patients originally randomized to placebo: 2-year results from the POETYK PSO program

Lead author: Mark Lebwohl, Icahn School of Medicine at Mount Sinai, New York, NY, USA

P2431: Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO-1 and POETYK LTE trials

Lead author: Mark Lebwohl, Icahn School of Medicine at Mount Sinai, New York, NY, USA

P2424: Efficacy of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: findings from the phase 3 POETYK PSO-1 trial

Lead author: Min Zheng, Zhejiang University School of Medicine, Hangzhou, China

P2434: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: improvement in body surface area involvement in the phase 3 POETYK PSO-3 trial

Lead author: Jianzhong Zhang, Peking University People’s Hospital, Beijing, China

P2426: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: absolute Psoriasis Area and Severity Index outcomes in the phase 3 POETYK PSO-3 trial

Lead author: Jianzhong Zhang, Peking University People’s Hospital, Beijing, China

P2436: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: onset of action and maintenance of response in the phase 3 POETYK PSO-3 trial

Lead author: Jianzhong Zhang, Peking University People’s Hospital, Beijing, China

P2446: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with plaque psoriasis: maintenance of response in the phase 3 POETYK PSO-3 trial

Lead author: Jianzhong Zhang, Peking University People’s Hospital, Beijing, China

P2435: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with scalp, palmoplantar, and nail psoriasis: subgroup analysis of the phase 3 POETYK PSO-3 trial

Lead author: Jianzhong Zhang, Peking University People’s Hospital, Beijing, China

P2437: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: safety findings from the phase 3 POETYK PSO-3 trial

Lead author: Jianzhong Zhang, Peking University People’s Hospital, Beijing, China

P2438: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: laboratory parameters from the phase 3 POETYK PSO-3 trial

Lead author: Jianzhong Zhang, Peking University People’s Hospital, Beijing, China

P2433: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis in Japanese patients with plaque psoriasis: subset analysis of the phase 3 POETYK PSO-4 trial

Lead author: Shinichi Imafuku, Fukuoka University Hospital, Fukuoka, Japan

P2394: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque psoriasis: safety findings from the phase 3 POETYK PSO-4 trial

Lead author: Akimichi Morita, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

P2395: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque psoriasis: laboratory parameters in the phase 3 POETYK PSO-4 trial

Lead author: Shinichi Imafuku, Fukuoka University Hospital, Fukuoka, Japan

P2432: Non-clinical evaluations of deucravacitinib and Janus kinase inhibitor specificity in inflammatory or homeostatic pathways

Lead author: Brandon Johnson, Bristol Myers Squibb, Princeton, NJ, USA

Dermatology HEOR: Oral Presentations

FC05.5: Deucravacitinib significantly improves symptoms and signs of psoriasis in patients with moderate to severe psoriasis: results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials

Presenter: Kim A. Papp, Probity Medical Research, Waterloo, ON, Canada

Presentation date and time: 13 October, 9:10 AM-9:20 AM CET

Location: Messe Berlin Congress Center (Room M1+2)

FC05.6: Deucravacitinib, an oral selective tyrosine kinase 2 inhibitor, vs placebo and apremilast in moderate to severe plaque psoriasis: subgroup analyses of phase 3 studies examining Psoriasis Symptom and Sign Diary and Dermatology Life Quality Index scores

Presenter: Joseph F. Merola, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Presentation date and time: 13 October, 9:20 AM-9:30 AM CET

Location: Messe Berlin Congress Center (Room M1+2)

FC05.7: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, improves outcomes in plaque, generalized pustular, or erythrodermic psoriasis in Japan: results from the POETYK PSO-4 study

Presenter: Joe Zhuo, Bristol Myers Squibb, Princeton, NJ, USA

Presentation date and time: 13 October, 9:30 AM-9:40 AM CET

Location: Messe Berlin Congress Center (Room M1+2)

Dermatology HEOR: Online e-Posters

P0778: Deucravacitinib improves symptoms and quality of life in patients with psoriasis: patient-reported outcomes at 2 years in the POETYK long-term extension study

Lead author: Steven R. Feldman, Wake Forest University School of Medicine, Winston-Salem, NC, USA

P2486: Registry of psoriasis health outcomes: a longitudinal real-world collaboration (RePhlect)—global registry design and approach

Lead author: April W. Armstrong, University of California Los Angeles, Los Angeles, CA, USA

P2423: The Registry of Psoriasis Health Outcomes: a longitudinal real-world collaboration study (RePhlect) – North American Registry Design

Lead author: Mark Lebwohl, Icahn School of Medicine at Mount Sinai, New York, NY, USA

P2488: A literature review of real-world evidence from psoriasis patient registries and its role in decision-making

Lead author: Lauren Passero, University of North Carolina, Chapel Hill, NC, USA

P2342: Undertreatment and mistreatment in psoriasis therapy? Quantification using registry and claims data in Germany

Lead author: Beke Hester, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

P2391: Trial-in-progress - deucravacitinib in routine clinical practice: a 5-year, multicenter, prospective, non-interventional cohort study to evaluate effectiveness and quality of life in patients with moderate to severe plaque psoriasis in Germany (DELPHIN)

Lead author: Ralph von Kiedrowski, Company for Medical Study & Service (CMSS)-Selters, Selters, Germany

P2502: Prescription patterns, treatment experience, and prescription preferences for systemic treatments for moderate to severe psoriasis among Chinese dermatologists: a cross-sectional survey study

Lead author: Yehong Kuang, Xiangya Hospital of Central South University, Changsha, China

P2457: Patient characteristics and treatment pattern among patients with moderate-to-severe plaque psoriasis using systemic treatment in China: real-world evidence from a retrospective observational study

Lead author: Xueyuan Yang, Hospital for Skin Diseases, Institute of Dermatology, Nanjing, China

P0780: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in Asian patients with moderate to severe psoriasis: maintenance of improvements in patient-reported outcomes 

Lead author: Jianzhong Zhang, Peking University People’s Hospital, Beijing, China

P0769: Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical response in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2

Lead author: April W. Armstrong, University of California Los Angeles, Los Angeles, CA, USA

P2483: Deucravacitinib improves Dermatology Life Quality Index in patients with moderate to severe psoriasis: results from the phase 3 POETYK PSO-1 and PSO-2 trials

Lead author: Matthias Augustin, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

P0768: Cumulative clinical benefit over 52 weeks comparing initiation with deucravacitinib versus apremilast in patients with moderate to severe plaque psoriasis: a post hoc analysis of POETYK PSO-1 trial results stratified by prior treatment

Lead author: April W. Armstrong, University of California Los Angeles, Los Angeles, CA, USA

P0783: Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial

Lead author: April W. Armstrong, University of California Los Angeles, Los Angeles, CA, USA

P2503: Characteristics of patients with moderate to severe psoriasis initiating systemic drug therapy in France and evolution of treatment sequences: a national observation study

Lead author: Isabelle Durand-Zaleski, CRESS, Université de Paris, Paris, France

P0782: Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: a systematic literature review and network meta-analysis

Lead author: Tsen-Fang Tsai, National Taiwan Hospital, Taipai, Taiwan

P2504: Trade-offs and decision-making in moderate to severe psoriasis for oral vs injectable treatment: data from Australian patients and dermatologists

Lead author: Saxon D. Smith, ANU Medical School, College of Health and Medicine, Australian National University, Canberra, Australia

P2484: Evaluating prevalence and consequence of residual disease among patients with moderate to severe psoriasis in the United States

Lead author: April W. Armstrong, University of California Los Angeles, Los Angeles, CA, USA

P2482: Assessing humanistic burden among patients with moderate to severe psoriasis in the United States

Lead author: April W. Armstrong, University of California Los Angeles, Los Angeles, CA, USA

P2478: Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy

Lead author: Sang Hee Park, Bristol Myers Squibb, Princeton, NJ, USA

P0766: Indirect comparison of the short-, mid-, and long-term efficacy of treatments for moderate to severe plaque psoriasis: a systematic review and network meta-analysis

Lead author: April W. Armstrong, University of California Los Angeles, Los Angeles, CA, USA

P0772: Matching-adjusted indirect comparison of long-term efficacy between deucravacitinib and adalimumab in patients with moderate to severe plaque psoriasis

Lead author: April W. Armstrong, University of California Los Angeles, Los Angeles, CA, USA

Rheumatology Clinical: Oral Presentation

FC04.1: Design of a phase 2, double-blind, placebo-controlled, global trial of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active discoid and/or subacute cutaneous lupus erythematosus

Presenter: Victoria Werth, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Presentation date and time: 12 October, 4:00 PM-4:10 PM CET

Location: Messe Berlin Congress Center (Room M1+2)

Rheumatology Clinical: Online e-Poster

P2429: Impact of oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, on psoriasis in patients with active psoriatic arthritis: results from a phase 2 trial

Lead author: Alice B. Gottlieb, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Rheumatology HEOR: Online e-Poster

P0777: Deucravacitinib, an oral, allosteric, selective tyrosine kinase 2 inhibitor, in patients with plaque psoriasis who screened positive for psoriatic arthritis in POETYK PSO-1 and PSO-2: effect on joint pain and peripheral joint disease vs placebo and apremilast

Lead author: Joseph F. Merola, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Early Assets: Online e-Poster

P0606: BMS-986326 is a novel IL-2/CD25 fusion protein that induces highly selective and durable expansion of regulatory T cells in vitro and following single doses in healthy volunteers

Lead author: Alice Wang, Bristol Myers Squibb, Princeton, NJ, USA

© 2023 Bristol Myers Squibb. All rights reserved.

This compendium may represent investigational, unapproved uses of some products listed.

Individual QR (Quick Response) codes will remain active for 30 days after the congress presentation date. Copies of presentations obtained through QR codes contained in this compendium are for personal use only and may not be reproduced without written permission from EADV and the authors. This compilation of presentations is intended as an educational resource and is for the exchange of scientific data with clinical investigators and healthcare professionals.